Purilogics offers a portfolio of purification tools for a range of biologics, including mRNA, plasmid DNA, viral particles, monoclonal antibodies and proteins. The company’s proprietary formulations and processes create membranes that enable faster and more cost-effective production of increasingly complex biologic drugs.
“We are excited about the value Purilogics brings to the Donaldson life sciences portfolio through its novel and differentiated products,” said Tod Carpenter, chairman, president and CEO of Donaldson. “Our membrane technology expertise, and global sales and manufacturing footprint, will enable faster development and commercialization of these powerful tools for biologics purification.”
“Being a part of Donaldson will provide Purilogics with the global scale and financial flexibility needed to achieve our founding vision – to accelerate the speed of early stage biologics drug development and improve production efficiency,” said Jinxiang Zhou, PhD, co-founder and vice president of Purilogics.
Founded in 2013 by Jinxiang Zhou, PhD and Scott Husson, PhD, Purilogics is headquartered in Greenville, South Carolina, USA.
Donaldson acquired Purilogics for an initial purchase price of approximately US$20 million as well as milestone-based earnout payments over the next five years. Once commercialised, revenue from Purilogics’ products will be reported within the Donaldson Industrial Filtration Solutions business in the Industrial Products segment.
